IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科
学科主题临床医学
Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
Zheng, Xiaohui; Ding, Ning; Song, Yuqin; Feng, Lixia; Zhu, Jun
关键词Germinal Center b Cell-like Diffuse Large b Cell Lymphoma Bruton&Prime s Tyrosine Kinase Bcr Apoptosis
刊名CANCER CELL INTERNATIONAL
2014-04-03
DOI10.1186/1475-2867-14-32
14
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]CHRONIC LYMPHOCYTIC-LEUKEMIA ; BRUTON TYROSINE KINASE ; RITUXIMAB THERAPY ; PROTEIN-KINASE ; ACTIVATION ; SURVIVAL ; EXPRESSION ; INHIBITORS ; PCI-32765 ; MALIGNANCIES
英文摘要

Background: Although rituximab in the combination of CHOP chemotherapy has been widely used as the standard treatment for several kinds of B-cell non-Hodgkin lymphoma (B-NHL), a great number of B-NHL patients treated with this immunotherapy still develop primary and secondary resistance. Recently Bruton′s tyrosine kinase (Btk) inhibitor ibrutinib showed promising therapeutic effect in relapsed/refractory CLL and B-cell NHL, which provided essential alternatives for these patients.

Methods: The proliferation and apoptosis induction of tumor cells were measured by cell viability assay and Annexin-V staining. Western Blotting analysis and real-time PCR were used to detect the expression level of target proteins and chemokines production.

Results: We demonstrated that ibrutinib inhibited the proliferation and induced apoptosis of GCB-DLBCL cell lines through suppression of BCR signaling pathway and activation of caspase-3. Furthermore, the chemokines CCL3 and CCL4 production from tumor cells were also found to be attenuated by ibrutinib treatment. But different cell lines exhibited distinct sensitivity after ibrutinib treatment. Interestingly, the decreasing level of p-ERK after ibrutinib treatment, but not the basal expression level of Btk, correlated with different drug sensitivity.

Conclusions: Ibrutinib could be a potentially useful therapy for GCB-DLBCL and the decreasing level of p-ERK could become a useful biomarker to predict related therapeutic response.

语种英语
WOS记录号WOS:000334625400001
项目编号81201873 ; 81241073 ; 7132050
资助机构NSFC ; Beijing Natural Science Foundation ; "985" Basic Research Fund from Peking University
引用统计
被引频次:16[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52469
专题北京大学临床肿瘤学院_淋巴肿瘤内科
作者单位Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Zheng, Xiaohui,Ding, Ning,Song, Yuqin,et al. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment[J]. CANCER CELL INTERNATIONAL,2014,14.
APA Zheng, Xiaohui,Ding, Ning,Song, Yuqin,Feng, Lixia,&Zhu, Jun.(2014).Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment.CANCER CELL INTERNATIONAL,14.
MLA Zheng, Xiaohui,et al."Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment".CANCER CELL INTERNATIONAL 14(2014).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zheng, Xiaohui]的文章
[Ding, Ning]的文章
[Song, Yuqin]的文章
百度学术
百度学术中相似的文章
[Zheng, Xiaohui]的文章
[Ding, Ning]的文章
[Song, Yuqin]的文章
必应学术
必应学术中相似的文章
[Zheng, Xiaohui]的文章
[Ding, Ning]的文章
[Song, Yuqin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。